Trading of Citius Oncology was halted at 12:13 PM EST due to "LULD pause". Positive News SentimentPositive NewsNASDAQ:CTOR Citius Oncology (CTOR) Stock Price, News & Analysis $4.94 +1.44 (+41.14%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Citius Oncology Stock (NASDAQ:CTOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Citius Oncology alerts:Sign Up Key Stats Today's Range$3.52▼$5.7250-Day Range$0.62▼$3.5052-Week Range$0.55▼$49.00Volume5.60 million shsAverage Volume1.15 million shsMarket Capitalization$353.46 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company OverviewCitius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Read More… Citius Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreCTOR MarketRank™: Citius Oncology scored higher than 9% of companies evaluated by MarketBeat, and ranked 907th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingCitius Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCitius Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Citius Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCitius Oncology has a P/B Ratio of 7.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CTOR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Oncology does not currently pay a dividend.Dividend GrowthCitius Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for CTOR. News and Social Media3.8 / 5News Sentiment1.89 News SentimentCitius Oncology has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.95 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Citius Oncology this week, compared to 0 articles on an average week.Search Interest5 people have searched for CTOR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.57% of the stock of Citius Oncology is held by insiders.Percentage Held by Institutions70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Citius Oncology's insider trading history. Receive CTOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CTOR Stock News HeadlinesCitius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025June 17, 2025 | prnewswire.comCitius Oncology stock soars on distribution dealJune 9, 2025 | in.investing.comIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't have happened at a worse time. Trump is already dealing with Biden's $34 trillion debt bomb AND now a Middle East war. This is exactly what the "resistance" has been waiting for.June 27 at 2:00 AM | American Alternative (Ad)Maxim Group Downgrades Citius Oncology (CTOR)May 24, 2025 | msn.comCitius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | prnewswire.comCitius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near FutureMay 7, 2025 | finance.yahoo.comCitius Oncology, Inc. Common Stock (CTOR) Institutional HoldingsMay 5, 2025 | nasdaq.comCitius Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 5, 2025 | prnewswire.comSee More Headlines CTOR Stock Analysis - Frequently Asked Questions How have CTOR shares performed this year? Citius Oncology's stock was trading at $1.15 at the beginning of 2025. Since then, CTOR stock has increased by 316.4% and is now trading at $4.7890. View the best growth stocks for 2025 here. How were Citius Oncology's earnings last quarter? Citius Oncology, Inc. (NASDAQ:CTOR) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. How do I buy shares of Citius Oncology? Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC). Company Calendar Last Earnings5/14/2025Today6/27/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTOR Previous SymbolNASDAQ:CTOR CIK1851484 Webwww.citiusonc.com Phone347-627-0058FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside-37.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on Equity-53.88% Return on Assets-18.86% Debt Debt-to-Equity Ratio0.11 Current Ratio0.36 Quick Ratio0.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book7.48Miscellaneous Outstanding Shares71,550,000Free Float68,282,000Market Cap$342.65 million OptionableN/A Beta-0.07 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:CTOR) was last updated on 6/27/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.